One step towards restoration of self-tolerance in human autoimmune diseases;Une étape vers la restauration de la tolérance immunitaire au soi dans les maladies auto-immunes humaines

Medecine/Sciences

Volumn 23, Issue 2, 2007, Pages 167-171

  Chatenoud, Lucienne ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CELL ANTIGEN; INSULIN; MONOCLONAL ANTIBODY CD3;

AUTOIMMUNE DISEASE; CONSERVATIVE TREATMENT; DEGENERATIVE DISEASE; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; EXPERIMENTAL STUDY; HUMAN; HYPOGLYCEMIA; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; PALLIATIVE THERAPY; PROPHYLAXIS; REMISSION; REVIEW; RISK FACTOR;

EID: 33847094119     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2007232167     Document Type: Review

References (42)

1. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance to foreign cells. Nature 1953 ; 172 : 603-6.
2. Brent L, Courtenay T, Gowland G. Immunological reactivity of lymphoid cells after treatment with anti-lymphocytic serum. Nature 1967 ; 215 : 1461-4.
3. Dresser DW. Specific inhibition of antibody production. II. Paralysis induced in adult mice by small quantities of protein antigen. Immunology 1962 ; 5 : 378-88.
4. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004 ; 22 : 531-62.
5. Bach JF. Regulatory T cells under scrutiny. Nat Rev Immunol 2003 ; 3: 189-98.
6. Chatenoud L, Salomon B, Bluestone JA. Suppressor T cells. They're back and critical for regulation of autoimmunity! Immunol Rev 2001 ; 182 : 149-63.
7. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrine Rev 1994 ; 15 : 516-42.
8. Kaufman DL, Clare-Salzler M, Tian J, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993 ; 366 : 69-72.
9. Tisch R, Yang X D, Singer SM, et al. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993 ; 366 : 72-5.
10. Elias D, Meilin A, Ablamunits V, et al. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens. Diabetes 1997 ; 46 : 758-64.
11. Tian J D, Claresalzler M, Herschenfeld A, et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 1996 ; 2 : 1348-53.
12. Tian J, Lehmann PV, Kaufman DL. Determinant spreading of T helper cell 2 (Th2) responses to pancreatic islet autoantigens. J Exp Med 1997 ; 186 : 2039-43.
13. Sospedra M, Martin R. Antigen-specific therapies in multiple sclerosis. Int Rev Immunol 2005 ; 24 : 393-413.
14. Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993 ; 259 : 1321-4.
15. Barnett ML, Kremer JM, St Clair EW, et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 1998 ; 41 : 290-7.
16. Barnett ML, Combitchi D, Trentham DE. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum 1996 ; 39 : 623-8.
17. Nussenblatt RB, Gery I, Weiner HL, et al. Treatment of uveitis by oral administration of retinal antigens: Results of a phase I/II randomized masked trial. Am J Ophthalmol 1997 ; 123 : 583-92.
18. Chaillous L, Lefevre H, Thivolet C, et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete insuline orale group. Lancet 2000 ; 356 : 545-9.
19. Ergun-Longmire B, Marker J, Zeidler A, et al. Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes. Ann NY Acad Sci 2004 ; 1029 : 260-77.
20. Skyler J. Effects of insulin in relatives of patients with type 1 diabetes mellitus. Diabetes prevention trial-type 1 diabetes study group. N Engl J Med 2002 ; 346 : 1685-91.
21. Raz I, Elias D, Avron A, et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001 ; 358 : 1749-53.
22. Brocke S, Gijbels K, Allegretta M, et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996 ; 379 : 343-6.
23. Clevers H, Alarcon B, Wileman T, et al. The T cell receptor/CD3 complex: a dynamic protein ensemble. Annu Rev Immunol 1988 ; 6 : 629-62.
24. Chatenoud L, Primo J, Bach J F. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997 ; 158 : 2947-54.
25. Chatenoud L, Thervet E, Primo J, et al. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994 ; 91 : 123-7.
26. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 2003 ; 3 : 123-32.
27. Belghith M, Bluestone JA, Barriot S, et al. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003 ; 9 : 1202-8.
28. Yasunami R, Bach JF. Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur J Immunol 1988 ; 18 : 481-4.
29. Mahiou J, Walter U, Lepault F, et al. In vivo blockade of the Fas-Fas ligand pathway inhibits cyclophosphamide-induced diabetes in NOD mice. J Autoimmun 2001 ; 16 : 431-40.
30. Cosimi AB, Colvin RB, Burton RC, et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 1981 ; 305 : 308-14.
31. Ortho multicenter transplant study group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985 ; 313 : 337-42.
32. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990 ; 49 : 697-702.
33. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989 ; 47 : 606-8.
34. Kohm AP, Williams JS, Bickford AL, et al. Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol 2005 ; 174 : 4525-34.
35. Ludviksson BR, Ehrhardt RO, Strober W. TGF-beta production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonic inflammation in IL-2-deficient mice. J Immunol 1997 ; 159 : 3622-8.
36. Alegre ML, Peterson LJ, Xu D, et al. A non-activating «humanized» anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994 ; 57 : 1537-43.
37. Bolt S, Routledge E, Lloyd I, et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993 ; 23 : 403-11.
38. Woodle ES, Xu D, Zivin RA, et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999 ; 68 : 608-16.
39. Friend PJ, Hale G, Chatenoud L, et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 1999 ; 68 : 1632-7.
40. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002 ; 346 : 1692-8.
41. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005 ; 54 : 1763-9.
42. Keymeulen B, Vandemeulebroucke E, Ziegler A G, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005 ; 352 : 2598-608.